The landscape of dementia analysis has evolved radically with the advent of advanced biomarkers, which include amyloid PET scans, tau imaging, and blood-primarily based assessments that may detect Alzheimer's pathology several years just before indications emerge. Though these technological developments stand for remarkable development in comprehen